Plasma Myeloperoxidase and Total Sialic Acid As Prognostic Indicators in Acute Coronary Syndrome

Overview

Journal J Clin Diagn Res

Specialty General Medicine

Date 2016 Sep 23

PMID 27656431

Citations 4

Authors

Sumitra Govindarajan

Vm Mithun Raghavan

Anand C Vasudeva Rao

Affiliations

Soon will be listed here.

Abstract

Introduction: Acute Coronary Syndrome (ACS) is the leading cause of death worldwide. Oxidative stress and inflammation play important role in the destabilization of plaques leading to ACS. Markers which reflect this pathophysiologic mechanism may have prognostic value. Myeloperoxidase (MPO) and Sialic acid are markers of inflammation and oxidative stress. Both these markers are increased in patients with ACS. Their prognostic value in ACS is not well established.

Aim: To analyse the prognostic value of plasma myeloperoxidase and total sialic acid levels in patients with suspected acute coronary syndrome.

Materials And Methods: A prospective study was conducted on 93 consecutively admitted patients with chest pain from July 2011 to September 2011. Plasma MPO and total sialic acid levels on admission were estimated spectrophotometrically. These were compared with extent of disease, development of complications during the hospital stay, left ventricular ejection fraction and mean duration of stay in hospital.

Results: Plasma MPO and total sialic acid levels were significantly higher in patients with myocardial infarction than those with unstable and stable angina (p<0.001 and p<0.007 respectively). The levels of plasma MPO and sialic acid levels were significantly higher in patients who developed complications like heart failure, arrhythmias, renal failure during their stay in hospital (p<0.011 and p<0.006 respectively). Ejection fraction was significantly low in patients with high MPO levels (p<0.011).

Conclusion: In patients with ACS, plasma MPO and total sialic acid levels on admission could predict the development of complications during their hospital stay. MPO levels correlated with ejection fraction in patients with ACS.

Citing Articles

Novel Biomarkers and Their Role in the Diagnosis and Prognosis of Acute Coronary Syndrome.

Katsioupa M, Kourampi I, Oikonomou E, Tsigkou V, Theofilis P, Charalambous G Life (Basel). 2023; 13(10).

PMID: 37895374 PMC: 10608753. DOI: 10.3390/life13101992.

Lipoprotein sialylation in atherosclerosis: Lessons from mice.

Yu L, Peng J, Mineo C Front Endocrinol (Lausanne). 2022; 13:953165.

PMID: 36157440 PMC: 9498574. DOI: 10.3389/fendo.2022.953165.

Neutrophil degranulation and myocardial infarction.

Zhang N, Aiyasiding X, Li W, Liao H, Tang Q Cell Commun Signal. 2022; 20(1):50.

PMID: 35410418 PMC: 8996539. DOI: 10.1186/s12964-022-00824-4.

Evaluation of Serum Levels of Inflammation, Fibrinolysis and Oxidative Stress Markers in Coronary Artery Disease Prediction: A Cross-Sectional Study.

Abolhasani S, Valizadeh Shahbazloo S, Saadati H, Mahmoodi N, Khanbabaei N Arq Bras Cardiol. 2019; 113(4):667-674.

PMID: 31482948 PMC: 7020864. DOI: 10.5935/abc.20190159.

References

Biasucci L, Liuzzo G, Grillo R, Caligiuri G, Rebuzzi A, Buffon A . Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation. 1999; 99(7):855-60. DOI: 10.1161/01.cir.99.7.855. View

Gungor Kaya M, Yalcin R, Okyay K, Poyraz F, Bayraktar N, Pasaoglu H . Potential role of plasma myeloperoxidase level in predicting long-term outcome of acute myocardial infarction. Tex Heart Inst J. 2012; 39(4):500-6. PMC: 3423276. View

Eiserich J, Baldus S, Brennan M, Ma W, Zhang C, Tousson A . Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science. 2002; 296(5577):2391-4. DOI: 10.1126/science.1106830. View

Bradley P, Christensen R, ROTHSTEIN G . Cellular and extracellular myeloperoxidase in pyogenic inflammation. Blood. 1982; 60(3):618-22. View

Finegold J, Asaria P, Francis D . Mortality from ischaemic heart disease by country, region, and age: statistics from World Health Organisation and United Nations. Int J Cardiol. 2012; 168(2):934-45. PMC: 3819990. DOI: 10.1016/j.ijcard.2012.10.046. View

Knuiman M, Watts G, Divitini M . Is sialic acid an independent risk factor for cardiovascular disease? A 17-year follow-up study in Busselton, Western Australia. Ann Epidemiol. 2004; 14(9):627-32. DOI: 10.1016/j.annepidem.2003.09.017. View

Nigam P, Narain V, Kumar A . Sialic acid in cardiovascular diseases. Indian J Clin Biochem. 2012; 21(1):54-61. PMC: 3453784. DOI: 10.1007/BF02913067. View

Fu X, Kassim S, Parks W, Heinecke J . Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J Biol Chem. 2001; 276(44):41279-87. DOI: 10.1074/jbc.M106958200. View

Schindhelm R, van der Zwan L, Teerlink T, Scheffer P . Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification?. Clin Chem. 2009; 55(8):1462-70. DOI: 10.1373/clinchem.2009.126029. View

10.

Lindberg G, Eklund G, Gullberg B, Rastam L . Serum sialic acid concentration and cardiovascular mortality. BMJ. 1991; 302(6769):143-6. PMC: 1668795. DOI: 10.1136/bmj.302.6769.143. View

11.

Rastam L, Lindberg G, Folsom A, Burke G, Nilsson-Ehle P, Lundblad A . Association between serum sialic acid concentration and carotid atherosclerosis measured by B-mode ultrasound. The ARIC Investigators. Atherosclerosis Risk in Communities Study. Int J Epidemiol. 1996; 25(5):953-8. DOI: 10.1093/ije/25.5.953. View

12.

Libby P, Tabas I, Fredman G, Fisher E . Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res. 2014; 114(12):1867-79. PMC: 4078767. DOI: 10.1161/CIRCRESAHA.114.302699. View

13.

Mocatta T, Pilbrow A, Cameron V, Senthilmohan R, Frampton C, Richards A . Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol. 2007; 49(20):1993-2000. DOI: 10.1016/j.jacc.2007.02.040. View

14.

Berkan O, Sagban M . Sialic acid or troponin T to detect perioperative myocardial damage in patients undergoing elective coronary artery bypass grafting. Circ J. 2002; 66(11):1019-23. DOI: 10.1253/circj.66.1019. View

15.

Gokmen S, Kilicli G, Ozcelik F, Gulen S . Serum total and lipid-bound sialic acid levels following acute myocardial infarction. Clin Chem Lab Med. 2001; 38(12):1249-55. DOI: 10.1515/CCLM.2000.197. View

16.

Carr A, McCall M, Frei B . Oxidation of LDL by myeloperoxidase and reactive nitrogen species: reaction pathways and antioxidant protection. Arterioscler Thromb Vasc Biol. 2000; 20(7):1716-23. DOI: 10.1161/01.atv.20.7.1716. View

17.

Sugiyama S, Kugiyama K, Aikawa M, Nakamura S, Ogawa H, Libby P . Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol. 2004; 24(7):1309-14. DOI: 10.1161/01.ATV.0000131784.50633.4f. View

18.

Serdar Z, Serdar A, Altin A, Eryilmaz U, Albayrak S . The relation between oxidant and antioxidant parameters and severity of acute coronary syndromes. Acta Cardiol. 2007; 62(4):373-80. DOI: 10.2143/AC.62.4.2022281. View

19.

Chang L, Chua S, Sheu J, Wu C, Yeh K, Yang C . Level and prognostic value of serum myeloperoxidase in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ J. 2009; 73(4):726-31. DOI: 10.1253/circj.cj-08-0577. View

20.

Suer Gokmen S, Kilicli G, Ozcelik F, Ture M, Gulen S . Association between serum total and lipid-bound sialic acid concentration and the severity of coronary atherosclerosis. J Lab Clin Med. 2002; 140(2):110-8. DOI: 10.1067/mlc.2002.126344. View